The portfolio of the Russian biopharmaceutical company PSK Pharma now features another drug, sugammadex, which is used in anesthesiology and intensive care. The Ministry of Health of the Russian Federation has registered the drug Sudzhecta in the form of an intravenous solution in two dosages (2 ml and 5 ml), the company’s press service reported. This is an analog of MSD’s Bridan. The patent for the molecule of the original drug expires in Russia in May 2025.
Sugammadex is used in anesthesiology and intensive care to reverse steroidal non-depolarizing neuromuscular blocking drugs rocuronium bromide or vecuronium bromide in adults, as well as children and adolescents aged 2 to 17 years. It is used for the reversal of nerve-blocking agents, restoring the patient’s independent breathing after surgery.
The domestic generic version of the drug will be produced at PSK Pharma’s plant of Dubna Technology and Innovation SEZ, in accordance with GMP standards. The drug is included in the list of VED.
In 2024, Sotex also received a registration certificate for Russia’s first sugammadex-based drug, which it brands as Destinil. The drug belongs to the class of selective antagonists of muscle relaxants. The Federal Antimonopoly Service of Russia announced that the price of Destinil has decreased by an average of 33% compared to the registered prices of the foreign reference drug.
Earlier, PSK Pharma reported that they had received registration certificates for two other drugs. One is Russia’s first medicine with INN tirofiban; branded as Tirofiban PSK, it is used for the treatment of acute coronary syndromes. It is supplied as a concentrate for the preparation of an infusion solution. The Ministry of Health also registered Ambrisentan PSK, Russia’s generic version of GSK’s Volibris, for the treatment of pulmonary arterial hypertension.
